


Supplementary Figure 4



Supplementary Figure 4 (related to Figure 3). Rab27a inhibitor Nexinhib20 impairs extracellular vesicles secretion in PDAC. (A) Representative photos of H&Es and anti-human MUC1 IHC of a PDX and Panc02 cell line orthotopic models. **(B)** Quantification of the number of particles measured by nanoparticle tracking analysis secreted in PDAC GEMMs cells cultured *ex vivo* (1 KPC, and 2 KPPC; n=3) and PDX cells cultured *ex vivo* (n=5) treated with DMSO 5% or Nexinhib20 (paired t-test $**p<0.01$). **(C,D,E)** Western blot for CD63 **(C)**, β -actin **(D)**, acetyl-cholinesterase and cytochrome C **(E)** in EVs isolated from DMSO (5%) or Nexinhib20 (1 μ M) treated MIA PaCa-2 cells. Cell lysates were used as positive control for cytochrome C and acetyl-cholinesterase. **(F)** Quantification of cell viability of the MIA PaCa-2 cell line cultured with different concentrations of Nexinhib20. Arrow indicates Nexinhib20 concentration used for *ex vivo* treatments. Data are mean \pm SEM.